Elicio Therapeutics, Inc. (ELTX)
Elicio Therapeutics, Inc. (ELTX)
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Depreciation | NaN | NaN | NaN | 106 |
| Net loss | -11,823 | -7,718 | -10,083 | -21,770 |
| Depreciation | 46 | 49 | 55 | 100 |
| Amortization of right-of-use assets, operating leases | 243 | 237 | 234 | 453 |
| Non-cash interest expense | NaN | -496 | 384 | 219 |
| Accrued expenses | NaN | NaN | 107 | -3,309 |
| Non-cash interest expense | 0 | NaN | NaN | NaN |
| Loss on issuance of warrants | NaN | 0 | 0 | 0 |
| Amortization of debt discount | 68 | 182 | 0 | 35 |
| Gain on disposal of property and equipment | NaN | 0 | 0 | 0 |
| Costs expensed upon the issuance of warrants | NaN | 0 | 0 | NaN |
| Change in fair value of warrant liabilities | 984 | -1,262 | 1,811 | 1,366 |
| Stock-based compensation | 868 | 772 | 698 | 1,227 |
| Prepaid expenses and other current assets | 504 | -106 | 344 | -1,387 |
| Other long-term prepaid assets | 225 | 0 | 170 | 0 |
| Accounts payable | -460 | 351 | -3,544 | 2,827 |
| Accrued expenses | -602 | -1,988 | NaN | NaN |
| Proceeds from issuance of common stock from at-the-market offerings, net of issuance costs | NaN | NaN | 11,385 | NaN |
| Deferred research obligation | 0 | 0 | 0 | -1,169 |
| Proceeds from june 2025 promissory note, net of issuance costs | NaN | 0 | 0 | 9,866 |
| Operating lease liabilities | -240 | -232 | -228 | -441 |
| Proceeds from issuance of common stock warrants from march 2024 offering | NaN | 0 | 0 | 0 |
| Net cash used in operating activities | -11,645 | -6,797 | -11,086 | -19,069 |
| Proceeds from issuance of common stock warrants from july 2024 public offering | NaN | 0 | NaN | NaN |
| Purchases of property and equipment | NaN | 16 | 0 | 0 |
| Proceeds from issuance of common stock from at-the-market offerings, net of issuance costs | NaN | 13,393 | NaN | 2,851 |
| Proceeds from sale of property and equipment | NaN | 0 | 0 | 0 |
| Proceeds from issuance of common stock from july 2024 public offering | NaN | 0 | NaN | NaN |
| Proceeds from issuance of common stock from at-the-market offerings, net of issuance costs | 7,988 | NaN | NaN | NaN |
| Net cash used in investing activities | NaN | -16 | 0 | 0 |
| Payment of warrant issuance costs | NaN | 0 | 0 | NaN |
| Payment of offering costs for the issuance of common stock from at-the-market offering | 61 | NaN | NaN | NaN |
| Proceeds from issuance of convertible note, net of issuance costs | NaN | 0 | 0 | NaN |
| Proceeds from the exercise of common warrants | 0 | 0 | 950 | 343 |
| Proceeds from issuance of common stock and common warrants from the january 2025 offering | 0 | 0 | 0 | 9,143 |
| Proceeds from the exercise of stock options | 100 | 4 | 88 | 57 |
| Net cash provided by financing activities | 8,027 | 4,863 | 9,572 | 22,260 |
| Effect of foreign currency on cash and cash equivalents | 5 | -96 | 39 | 105 |
| Net (decrease) increase in cash and cash equivalents | -3,613 | -2,046 | -1,475 | 3,296 |
| Cash, cash equivalents and restricted cash at the beginning of the period | 19,267 | 21,313 | 19,492 | NaN |
| Cash, cash equivalents, and restricted cash at the end of the period | 15,654 | 19,267 | 21,313 | NaN |